Arthritic Knee Pain
Conditions
Brief summary
The study objective is to determine whether a single intra-articular dose of an anti-inflammatory (Toradol) will reduce the need for other analgesic medications and, if so, how long the benefits will last.
Interventions
DRUGToradol
3-ml solution that contains 2 ml of normal saline and 1 ml of Toradol, 30 mg, will be infused into the affected joint.
DRUGOral NSAID
800mg Motrin will be administered. (non-steroidal anti-inflammatory drug (NSAID))
Sponsors
The University of Texas Health Science Center, Houston
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients with radiographic evidence of osteoarthritis (OA) who present to the ED with a chief complaint of knee pain that the treating provider attributes to their arthritis.
Exclusion criteria
* Acute knee trauma * Intra-articular steroid injection within 6 months * History of gout or rheumatoid arthritis * X ray evidence of pathologic fracture, malignancy, or other non-OA cause of symptoms * Signs or symptoms or high risk of acute infection: Recent fevers and chills; Erythema, warmth, or pain out of proportion to exam; History of hemodialysis; History of IV drug use * Lidocaine allergy * Any contraindication to NSAID therapy, including: Allergy; Pregnancy; History of renal insufficiency; History of gastritis, GERD or GI bleeding; Primary care physician's restriction of its use * Contraindication to the procedure, including: Hemophilia; History of total knee replacement of the affected joint * An inability to give informed consent; Active psychosis; Diminished capacity requiring another person to provide consent for medical treatment * An inability to be contacted for follow-up
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pain Medication Usage for Breakthrough Pain | 72 hours |
| Pain Level as Assessed by a Visual Analogue Scale | 72 hours |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Number of Participants who had a second visit to a Emergency Department or Clinic | 4 weeks | — |
| Pain Medication Usage for Breakthrough Pain | 1 week post treatment | The number of pills will be reported |
| Pain Level as Assessed by a Visual Analogue Scale | 1 week post treatment | — |
Outcome results
None listed